anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To display an easy-to-view picture even when there are many intracorporal structures at positions differing in depth direction. SOLUTION: Pixels within a specific CT value range are extracted from a three-dimensional model only within a range that an intracorporal structure that an operator specifies is extracted and the wall surface of an intracorporal structure (e.g. the colon D) which is most on this side when viewed from a viewpoint position and another body structure right behind it (e.g. a blood vessel B running nearby the mentioned wall surface) are made translucent to generate and display a three-dimensional image in endoscope mode like an image wherein they are put one over the other. Consequently, only necessary structures can selectively be displayed, so the picture can clearly be displayed. This is useful in displaying the three-dimensional image in endoscope mode.
PURPOSE: There is no approved targeted therapy for chordoma at present. Although several preclinical studies have implied the potential applicability of CDK4/6 inhibitor for this rare tumor, no clinical evidence has been documented so far. The purpose of this study was to elucidate the therapeutic efficacy of CDK4/6 inhibitor for chordoma.
METHODS: The next generation sequencing (as for whole-exome sequencing, WES assay) and immunohistochemical (IHC) staining of the chordoma tissue from a patient with an advanced lesion were performed before treatment. Then, the patient was treated with Palbociclib for 4 months until progression occurred in the 5th month. Surgical resection was implemented and the tumor tissue was obtained postoperatively for assessment of molecular alterations.
RESULTS: Molecular features of the tumor before medical treatment suggested applicability of CDK4/6 inhibitor and the patient showed partial response (PR) according to Choi Criteria after 4 months treating with Palbociclib until progression occurred. Then, a drastic molecular alteration of the tumor as represented by emergence of dramatic E2F amplification, which is known to induce CDK4/6 independent cell-cycle entry and progression after treatment, was detected. The findings in this patient demonstrated tumor evolution under drug pressure.
CONCLUSION: The findings of the present study suggest the feasibility of Palbociclib for the clinical treatment of chordoma, and imply the necessity of combination therapies rather single drug administration due to the quick resistance of the tumor to Palbociclib treatment.
Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
The present invention relates to modified serpins for use in the treatment of bradykinin-mediated diseases. The modified serine protease inhibitors (serpins) have mutations in one or more of the P4, P3, P2, P1 and P1′ residues of their reactive center loop, which mutations increase the serpin's inhibition of plasma kallikrein (PK) as compared to the corresponding unmodified serpin. The mutations in the modified serpins of the invention further ensure that serpins display substantially no inhibition of at least thrombin and activated protein C. A modified serpin of the invention further preferably shows increased inhibition of at least one of an active form of Factor XII (FXII) and plasmin as compared to the corresponding unmodified serpin, and, preferably, the serpin inhibits at least one of an active form of FXII and PK stronger than they are inhibited by C1 esterase inhibitor. Preferably the modified serpin is a modified α1-antitrypsin. The invention further pertains to nucleic acid molecule encoding the modified serpins of the invention, e.g. a gene therapy vector, and to pharmaceutical compositions comprising the modified serpins of the invention or such gene therapy vectors.
<P>PROBLEM TO BE SOLVED: To provide a new protein synoviolin, and to provide a gene encoding the same.  <P>SOLUTION: This new antigen protein (synoviolin) has a specific amino acid sequence and is recognized by antisynoviocyte serum. This protein is expressed specifically in a synovial tissue and also accompanies the presence of an autoantibody that recognizes this protein in rheumatoid arthritis (RA) patients. This protein and the autoantibody can be expected to be used as specific diagnostic markers for RA and, in addition, permit the screening of drugs to treat RA. Moreover, synoviolin gene transgenic animals can be used as RA model animals in the development of pharmaceuticals to treat RA.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Adult patients (18 years or older) meeting Sepsis-3 criteria within 6 hours of emergency department admission. Patients will be excluded with the following conditions: traumatic injury, cardiac arrest, stroke, comfort measures only.
Inflammation is a part of the body's intricate biological reaction to noxious stimuli and defensive reactions. So, the aim of this investigation was to study the anti-inflammatory activity of exopolysaccharide (EPSSM) using carrageenan-induced paw edema in rats. A halophilic bacterial strain was isolated from marine sediments in the Red Sea in Egypt. The isolate has been visually and physiologically recognized, as well as by analyzing its 16S rRNA gene, which confirms Kocuria sp. clone Asker4. This particular isolate can be referenced using the accession number OL798051.1. EPSSM was subjected to purification and fractionation by a DEAE-cellulose column. Preliminary chemical analysis of EPSSM indicated that the monosaccharides were fructose, glucuronic acid, and xylose, with 2.0, 0.5, and 1.0, respectively. The antioxidant potential of EPSSM was investigated, and it was discovered that the level of activity increased independently of the concentrations, reaching a maximum threshold of 94.13% at 100 µg/mL of EPSSM for 120 min. Also, EPSSM at 50 mg/kg orally produced a significant anti-inflammatory effect on the carrageenan model at 2, 3, and 4 intervals. The EPSSM intervention resulted in reductions in the levels of catalase and superoxide dismutase enzymes, as well as a decrease in glutathione. Furthermore, the levels of nitric oxide, lipid peroxidation, and reactive oxygen species resulting from carrageenan-induced edema showed a significant reduction subsequent to the administration of EPSSM. Moreover, the findings indicated that the protein expression levels of cyclooxygenase-2 and interleukin-6 were reduced following treatment with EPSSM, resulting in a reduction of paw edema.
The inner boot includes a body portion (2) enclosing the skier's foot and a leg portion (3) extending from it. A cut-out delimited by a pair of flap extends longitudinally of the leg portion. The flaps overlap one another and are held closed by a length of pull-out band (10) connected at one end to one of the flaps. The band engages a ring-like member (11) fitted to the opposite flap. A rear flap (20) partly overlies the lower part of the cut-out to improve ankle security. The leg and body portions are moulded together as an integral unit.
BACKGROUND: Limited research has investigated the relationship between small airway dysfunction (SAD) and static lung hyperinflation (SLH) in patients with post-acute sequelae of COVID-19 (PASC) especially dyspnea and fatigue.
METHODS: 64 patients with PASC were enrolled between July 2020 and December 2022 in a prospective observational cohort. Pulmonary function tests, impulse oscillometry (IOS), and symptom questionnaires were performed two, five and eight months after acute infection. Multivariable logistic regression models were used to test the association between SLH and patient-reported outcomes.
RESULTS: SLH prevalence was 53.1% (34/64), irrespective of COVID-19 severity. IOS parameters and circulating CD4/CD8 T-cell ratio were significantly correlated with residual volume to total lung capacity ratio (RV/TLC). Serum CD8 + T cell count was negatively correlated with forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) with statistical significance. Of the patients who had SLH at baseline, 57% continued to have persistent SLH after eight months of recovery, with these patients tending to be older and having dyspnea and fatigue. Post-COVID dyspnea was significantly associated with SLH and IOS parameters R5-R20, and AX with adjusted odds ratios 12.4, 12.8 and 7.6 respectively. SLH was also significantly associated with fatigue.
CONCLUSION: SAD and a decreased serum CD4/CD8 ratio were associated with SLH in patients with PASC. SLH may persist after recovery from infection in a substantial proportion of patients. SAD and dysregulated T-cell immune response correlated with SLH may contribute to the development of dyspnea and fatigue in patients with PASC.
The invention discloses talcum powder containing herbal natural components and a preparation process thereof. The talcum powder containing herbal natural components is prepared from the following raw materials in percentage by weight: 5%-70% of seawater pearls, 5%-20% of roses, 20%-85% of mung bean flour and 1%-2% of borneol. The preparation process of the talcum powder comprises the following steps: calcining the seawater pearls under the conditions that temperature is 70 DEG C-80 DEG C and humidity is 10%-30%; roasting roses with slow fire at 30 DEG C-50 DEG C for 30 minutes-120 minutes; and then, mixing the calcined seawater pearls and roasted roses with borneol and mung bean flour, crushing, sieving, drying and air curing to prepare the talcum powder. According to the talcum powder disclosed by the invention, all natural herbal components adopted are free from irritation to skin; the powder does not fly upwards, is fine, smooth, natural, pure and aromatic, and has effects of clearing damp, clearing away heat and toxic materials, enriching the blood, moistening dryness and promoting blood circulation to remove blood stasis. During use, the talcum powder can be sprayed, scattered, coated and spread on parts with more sweats. And moreover, the talcum powder has remarkable curative effect on eczema, scytitis, and the like caused by dampness and hidrosis, and especially has remarkable effects of treating infantile eczema and preventing prickly heat.
FIELD: cosmetic industry. SUBSTANCE: method involves applying cream masks on skin. Cream masks has gel as a base, bioactive plant and/or animal substances and osmotically active additions that are the nutrient medium for mammalian cells culturing. Cream masks: masks exhibiting hyperosmotic activity, at osmomolality value above 320 m-Osm/l, and that at hypoosmotic activity (below 280 m-Osm/l). Masks of both types were applied by turn at amount two or above for a single seance at one mask time applying at least for 15-20 min. EFFECT: enhanced effectiveness of masks. 3 cl
The invention discloses a short peptidoglycan recognition protein and a preparation method thereof, isolated nucleic acid and application thereof, and an antibacterial drug, and belongs to the technical field of molecular biology. The amino acid sequence of the short peptidoglycan recognition protein disclosed by the invention is SEQ ID NO. 1, or is a derivative sequence which is obtained by replacing and/or deleting one or more amino acid residues of the amino acid sequence shown by SEQ ID NO. 1 and has the same activity as the amino acid sequence shown by SEQ ID NO. 1. The short peptidoglycan recognition protein disclosed by the invention has obvious bacteriostatic effect on intracellular bacteria and extracellular bacteria, and has potential application value in the aspects of developing novel antibacterial drugs, immunopotentiators, health-care products, feed additives and the like.
Acute severe ulcerative colitis (ASUC), characterised by bloody diarrhoea and systemic inflammation, is associated with a significant risk of colectomy and a small risk of mortality. The landmark trial of cortisone in 1955 was pivotal for two reasons: first, for establishing the efficacy of a drug that remains a first-line therapy today and, second, for producing the first set of disease severity criteria and clinical trial endpoints that shaped the subsequent ASUC trial landscape. Trials in the 1990s and at the turn of the millennium established the efficacy of infliximab and ciclosporin, but since then, there has been little progress in drug development for this high-risk population. This systematic review evaluates all interventional randomised controlled trials (RCTs) conducted in patients hospitalised with severe UC. It provides an overview of the efficacy of treatments from past to present and assesses the evolution of trial characteristics with respect to study populations, eligibility criteria and study designs over time. This review details ongoing RCTs in this field and provides a perspective on the challenges for future clinical trial programmes and how these can be overcome to help deliver novel ASUC therapies.
PURPOSE: An antimicrobial peptide derived from Thunnus albacares is provided to show effective antimicrobial activity against fish pathogenic microorganisms without harming the fish and the human body because the peptide does not have a hemolytic activity to erythrocytes of human and fish. CONSTITUTION: A peptide with an amino acid sequence of sequence number 1 or a variant thereof has an antimicrobial activity. The peptide or the derivative is derived from Thunnus albacares. The peptide or the derivative has an antimicrobial activity against gram positive bacteria and gram negative bacteria. The peptide or the variant does not damage erythrocytes of human or fish. A gene encodes the peptide or the variant. Antibiotics contain the peptide as an active ingredient.
The invention relates to a drug-resistant staphylococcus aureus phage SP160 and application thereof in preparation of a bacteriostatic agent. The invention separates the phage from the sewage sample, which is a phage for cracking multi-drug resistant staphylococcus aureus, and the titer reaches 1.75X10  11  PFU/mL, designated SP160. Observed under electron microscope, the phage has long non-shrinking tail, belonging to the order of caudate phage and family of long caudate phage. The phage SP160 has a narrow cleavage spectrum, the optimal complex number of infection is 1000, and the results of cleavage kinetics show that the phage SP160 can inhibit bacterial growth, has stable activity in the range of-20 ℃ to 54 ℃, has stable activity between pH values of 3 to 11 and is sensitive to ultraviolet rays. SP160 has a scavenging effect on its host bacterial biofilm. The phage is a long-tail novel phage with narrow spectrum and certain tolerance to environment, and can provide theoretical materials for the research of staphylococcus aureus phage.
Noncommunicable diseases (NCDs) are the main cause of death globally (70%) and in the Region of the Americas (80%), and poor diets are a leading driver of NCDs. In response, the Pan American Health Organization (PAHO)/World Health Organization (WHO) introduced a set of evidence-based regulatory measures to help countries improve diets through the reduced consumption of processed and ultra-processed foods. This paper aims to describe the needs of and propose actions for key actors to advance these measures. A workshop was designed to assess member states' regulatory capacity. A thematic analysis was conducted to analyze regional needs, successes and challenges. Thereafter, the Government Capacity-Building Framework for the prevention and control of NCDs was used to examine findings. The findings were organized in two sets: (i) PAHO/WHO actions to support member states and (ii) key actors' actions to advance regulatory policies. The results show notable regulatory progress across the Region of the Americas. However, progress differs between countries, with opportunities to strengthen measures in most countries, mainly in conflict of interest management. The results identified important actions to strengthen the regulatory capacity of PAHO/WHO member states. To maximize momentum for these actions, timelines must be identified, and political commitment can be boosted by applying human rights-based and food system-wide approaches.
Spinal tuberculosis (TB) remains a significant global health concern, necessitating the development of innovative treatment strategies. This clinical study aimed to evaluate the efficacy and safety of endoscopic debridement as a minimally invasive approach for treating paravertebral abscesses in patients with spinal tuberculosis. A total of 52 patients diagnosed with paravertebral tuberculosis abscesses were enrolled in this retrospective study. Patients were assigned to two groups: the endoscopic debridement group (n = 30) and the conventional open surgery group (n = 22), based on the type of surgery they received. Clinical outcomes were assessed at baseline, post-treatment, and follow-up visits at regular intervals, including surgery time, intraoperative blood loss, total hospital stay duration, pain relief, and neurological improvement. The results of this study demonstrate that endoscopic debridement is a highly effective treatment for paravertebral abscesses in patients with spinal TB. Patients in the endoscopic debridement group experienced significant improvements in surgery time, intraoperative blood loss, total hospital stay duration, pain relief, and neurological improvement compared to those in the conventional open surgery group. Additionally, the endoscopic approach resulted in fewer complications, such as wound infections and postoperative instability, with no cases of recurrence observed during the follow-up period. Therefore, this clinical study highlights the potential of endoscopic debridement as a safe and effective treatment modality for spinal tuberculosis. The technique not only effectively eliminates infected tissue but also ensures faster patient recovery and reduces postoperative complications. Additional research and long-term follow-up studies are necessary to confirm the long-term effectiveness and safety of endoscopic debridement as the standard treatment for spinal tuberculosis.
PURPOSE: A composition containing Euphorbia supine extract for preventing or treating allergic diseases or inflammatory diseases is provided to be used in pharmaceutical products, quasi-products, and foods. CONSTITUTION: A composition for preventing or treating inflammatory diseases or allergic disease contains Euphorbia supine extract as an active ingredient. The extract is prepared using water, low carbon number alcohol, or a mixture solvent thereof. The low carbon number alcohol includes methanol, ethanol, or butanol. The inflammatory diseases include bronchitis, gastritis, diabetes, arthritis, obesity, inflammatory bowel disease(IBD), Alzheimer's disease, multiple sclerosis, tuberculosis, sarcoidosis, hepatitis, cholecystitis, fungous infection, gastric ulcer, asthma, atopic dermatitis, tendinitis or nephritis. The pharmaceutical composition additionally contains pharmaceutically acceptable carrier.
This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.
An anti-adhesion device in the form of a fillable balloon having a wall structure permits suturing or other attachment of the balloon to surrounding tissues. The balloon may be filled with a gas, liquid, or gel, and may be constructed of a resorbable material. The balloon may contain one or more growth factors and one or more antibodies to the growth factors may also be provided. Cytokines may be incorporated into the wall structure. The associated surgical procedure includes suturing or otherwise attaching the balloon between healing tissues and surrounding tissues. The healing tissues may include the vagina and the surrounding tissues include the small intestines, the great vessels and the spine following anterior spinal surgery, or any other appropriate location(s). The balloon may be placed immediately after an open surgical procedure or, alternatively, through smaller incisions as part of a minimally invasive procedure. Thus, the balloon may be filled prior to introduction or following placement. In the preferred embodiment the balloon ruptures and resorbs after the surgically treated tissues are partly or completely healed.
This study is a randomized controlled trial that will recruit parents/caregivers and infants infants living in the Greater Chicago area . The study will follow these infants until they are three years old.

The intervention arm will receive education about nutrition, resources, and specific instructions on feeding and caring for their infants. The control arm will receive education about infant development and helpful tips about infant sleep, screen time, and building healthy relationships. In addition, all caregivers will be asked to fill out surveys and come to research visits during the study period. There will be a total of 4 study visits during the three years of the study. There will be optional blood, stool, and skin testing of the child at each study visit. Two visits will take place during the first year of life, followed by visits around the child's 2nd and 3rd birthdays.
PURPOSE: A skin adhesion cosmetic formulation which is derived from a Papyrus plant is provided to ensure air permeability, moisture absorption, and tensile strength and to apply on the skin without irritation. CONSTITUTION: A skin adhesion cosmetic formulation contains a Papyrus plant-derived support and a gel containing an active ingredient. The gel is cross linking hydrogel or silicon gel. The support contains cyperus papyrus plant stem ingredient. The formulation is a mask pack. The active ingredient is anti-wrinkle ingredient of retinol, retinyl palmitate, adenosine, or polyethoxyrlated retinamide; a whitening ingredient of arbutin, paper mulberry extract, glycyrrhizae radix, ethyl ascorbyl ether, ascorbyl glucoside, or magnesium ascorbyl phosphate; a moisture ingredient of Schizophyllum commune polysaccharide, niacinamide, or N-acetylglucosamine; or anti-trouble ingredient of ivy extract, charmomile, or jujube extract.
PURPOSE: An MIF(macrophage migration inhibitory factor) secretion inhibitor is provided to be administered as an external skin formulation and to suppress MIF function. CONSTITUTION: An MIF secretion inhibitor contains Calendula officinalis extract. An external use skin formulation contains the inhibitor. An agent for treating inflammatory diseases contains the inhibitor. The extract is prepared from Calendula officinalis whole plant, flowers, leaves, stems, leaves, and roots using water, ethanol, ether, acetone, 1,3-butylene glycol, 1,2-pentandiol, propylene glycol, ethyl acetate. The extract also contains a fraction prepared by purifying the extract by various chromatographies. [Reference numerals] (AA) MIF secretion rate(%); (BB) Vehicle; (CC) 100% BG extract of Calendula officinalis